Ipamorelin + CJC-1295 Stack: Research Rationale & Sourcing

Q: Is the Ipamorelin + CJC-1295 stack different from taking CJC-1295 alone?

Yes. CJC-1295 alone stimulates the GHRH receptor pathway. Adding Ipamorelin activates the separate GHRP/ghrelin receptor pathway at the same time, which research on combined secretagogues suggests produces a stronger, more synchronized pulse of GH release than either compound alone.

Q: Which form of CJC-1295 is used in this stack?

Research protocols combining it with Ipamorelin typically use the non-DAC form (Mod GRF 1-29), since its shorter half-life more closely matches the timing Ipamorelin's pulsatile action is designed around, rather than the long-acting DAC variant.

Q: How is this different from a GHRP-6 + CJC-1295 stack?

Ipamorelin is a more selective GH secretagogue than GHRP-6 — it stimulates GH release with comparatively less effect on cortisol, prolactin, and appetite, which is the main reason it has become the more commonly discussed secretagogue partner for CJC-1295 in recent research.

The principle behind the stack

GH release runs through two separate switches at the pituitary: the GHRH receptor and the ghrelin (GHRP) receptor. CJC-1295 hits the first, Ipamorelin hits the second. Because they don't compete for the same receptor, flipping both at once produces a bigger, more synchronized GH pulse than either one alone — that's the entire case for stacking them.

A brief history of the research

Ipamorelin exists because earlier GHRP-family secretagogues (GHRP-6, GHRP-2) reliably pushed up cortisol, prolactin, and appetite right alongside GH. Its more selective binding is exactly why it replaced those older compounds as the go-to pairing partner for CJC-1295.

How this differs from CJC-1295 or Ipamorelin alone

CJC-1295 alone stretches out GH pulses that are already happening — it doesn't start new ones. Ipamorelin alone can trigger a pulse, but without CJC-1295's amplifying effect on its size. One triggers, one amplifies. That division of labor is the whole reason to stack them instead of picking just one.

Who runs this stack, and why

Three research angles account for nearly all the interest: recovery protocols studying GH's role in tissue repair between training cycles, longevity protocols examining whether a more youthful GH pulse shows up in age-related markers, and body-composition research narrowed to two levers — fat metabolism and lean mass. The stack format specifically gets chosen over either compound alone when a protocol wants to isolate that combined-pulse effect.

Pre-combined, verified, ready to go

No mixing two separate vials — this is the Ipamorelin/CJC-1295 blend, ≥99% purity, independent COA on every lot.

Check Availability

Want the deep dive on each compound separately?

For a full breakdown of CJC-1295 on its own — DAC vs. non-DAC forms, half-life, and independent research on the GHRH pathway — see our companion research guide, CJC Peptides Explained.

Reading a certificate of analysis (COA)

A trustworthy COA states the testing method (HPLC and mass spectrometry), the measured purity, the lot number, and the testing lab's identity. Cross-check the lot number on the vial against the published COA before relying on any research result.

Frequently Asked Questions

Is the Ipamorelin + CJC-1295 stack different from taking CJC-1295 alone?+

Yes — Ipamorelin activates a separate receptor pathway, so combining it with CJC-1295 is studied as a way to trigger a stronger, more synchronized GH pulse than either compound alone.

Which form of CJC-1295 is used in this stack?+

Typically the non-DAC form (Mod GRF 1-29), whose shorter half-life better matches Ipamorelin's pulsatile timing than the long-acting DAC variant.

How is this different from a GHRP-6 + CJC-1295 stack?+

Ipamorelin is more selective than GHRP-6 — it raises GH with less effect on cortisol, prolactin, and appetite, which is why it's become the more commonly discussed partner for CJC-1295.

The Ipamorelin / CJC-1295 Stack: Why Researchers Combine These Two Peptides